Have questions about our groundbreaking cancer therapies or partnership opportunities? Reach out to Theranib Inc. and join us in advancing cancer care worldwide.
Theranib’s US Patent Published
Theranib Inc. announces the publication of its US patent on January 9, 2025, securing protection for VE3, a groundbreaking ALDH1A3-targeted cancer therapy.
ALDH1A3 and Breast Cancer Progression
Explore the pivotal role of ALDH1A3 in breast cancer progression highlighted in a recent study, reinforcing Theranib’s mission to advance ALDH1A3-targeted therapies.
The Expanding Role of ALDH1A3 in Cancer
Discover the expanding role of ALDH1A3 in cancer stem cells and its therapeutic potential, reinforcing Theranib’s focus on precision-targeted cancer therapies.